NCT06278870View on ClinicalTrials.gov

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

June 30, 2031

Study Completion Date

June 30, 2031

Conditions
HER2-positive Metastatic Breast CancerFirst-line Treatment
Interventions
DRUG

disitamab vedotin

disitamab vedotin 2mg/kg iv q2w

DRUG

Pyrotinib

pyrotinib 400mg po q28d

DRUG

trastuzumab

trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d

DRUG

Pertuzumab

pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d

DRUG

taxane drug

Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER